The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...

Inavolisib showed promise in treating patients with PIK3CA-mutated solid tumors, demonstrating favorable safety and disease ...

This includes: CRC Data from GALAXY (Nature Medicine & ESMO Poster) In this study, 2,240 patients with stage II– IV CRC were monitored using Signatera after curative-intent surgery with a median ...

Research highlights the use of multimodal machine learning to identify non-small cell lung cancer patients predicted to ...

Overall, the Company believes that the results to date from the TAMARACK study indicate antitumor activity associated with vobra duo in mCRPC as demonstrated by the protocol-specified primary endpoint ...

Combination of masofaniten plus enzalutamide continues to be well tolerated with durable reductions in PSA in patients with ...

Enfortumab vedotin showed a robust disease control rate in patients with urothelial cancer outside of a clinical trial, and ...

Meredith McKean, MD, discusses a longer-term follow-up study investigating fianlimab and cemiplimab immunotherapy in advanced ...

Deepened, persistent responses were seen in the long term among patients with advanced melanoma treated with fianlimab and ...

- Expansion at RP2D is ongoing with an additional 23 patients enrolled to date; expansion data are expected in the first half of 2025 - ...

Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today a ...